BriMindInvest Logo

Merck & Co., Inc. (MRK) Stock Analysis 2026

HealthcareDrug Manufacturers - General
$127.77as of 2026-08-03

BriMind AI Score

Proprietary
50
Neutral
Price CAGR
11.9%
1Y Return
+64.2%
Analyst Upside
+3.8%
Rev Growth
4.9%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$154.71+21.1% potential
Bear Case
$99.97
Bull Case
$186.83
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

MRK Revenue & Profitability Breakdown

This chart shows how MRK's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$65.77B
Cost of Revenue
-$15.31B
Gross Profit
$50.46B76.7% margin
Operating Expenses
-$25.07B
Operating Income
$25.39B38.6% margin
Tax & Other
-$16.45B
Net Income
$8.94B13.6% margin
Gross Margin
76.7%
Operating Margin
38.6%
Net Margin
13.6%
EBITDA Margin
45.0%

Key Financial Metrics

A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.

Market Cap
$314.90B
Enterprise Value
$223.98B
P/E (Trailing)
36.68
P/E (Forward)
13.45
EV / EBITDA
7.78
Price / Sales
3.10
Price / Book
4.11
Revenue
$65.77B
Revenue Growth
4.9%
Earnings Growth
-19.3%
EBITDA
$28.80B
Gross Margin
76.7%
Operating Margin
38.6%
Net Margin
13.6%
Return on Equity
18.9%
Return on Assets
12.6%
Free Cash Flow
$14.05B
Total Cash
$9.23B
Total Debt
$34.84B
Debt / Equity
106.94
Current Ratio
1.30
Quick Ratio
0.70
Beta
0.20
Dividend Yield
2.6%
Payout Ratio
93.5%
Book Value / Share
$18.58

Wall Street Analyst Consensus

Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.

Consensus RatingBuy(24 analysts)
SellStrong Buy
Low Target$82.00-35.8%
Mean Target$135.19+5.8% upside
High Target$138.00+8.0%

Intrinsic Value Estimates for MRK

Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.

DCF Model (10yr)
$117.50
-8.0% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$117.50 – $117.50
Average Estimate
$117.50
Potential Downside
-8.0%

⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Compare MRK with Peers

MRK vs BMYMerck vs Bristol-Myers Squibb — Which Pharma Stock Is t
MRK vs ABBVMerck vs AbbVie — Oncology Leader vs Immunology Giant
LLY vs MRKEli Lilly vs Merck — GLP-1 Growth vs Keytruda Value
GILD vs MRKGilead Sciences vs Merck — Antiviral Specialist vs Keyt
ABBV vs MRKAbbVie vs Merck — Immunology Giant vs Keytruda Oncology
JNJ vs MRKJohnson & Johnson vs Merck — Which Pharma Dividend Stoc
PFE vs MRKPfizer vs Merck — Which Big Pharma Stock Wins?

MRK — Related Investment Themes

Top Biomedical & Pharma Stocks10 stocks in theme

Unlock the Full MRK Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
← Back to Home · Browse All Stock Analysis